Acura Pharmaceuticals Inc
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminoph… Read more
Acura Pharmaceuticals Inc (ACUR) - Total Assets
Latest total assets as of September 2021: $1.41 Million USD
Based on the latest financial reports, Acura Pharmaceuticals Inc (ACUR) holds total assets worth $1.41 Million USD as of September 2021.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Acura Pharmaceuticals Inc - Total Assets Trend (2000–2021)
This chart illustrates how Acura Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Acura Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2021)
Acura Pharmaceuticals Inc's total assets of $1.41 Million consist of 43.3% current assets and 56.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.6% |
| Accounts Receivable | $158.00K | 18.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2000–2021)
This chart illustrates how Acura Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Acura Pharmaceuticals Inc's current assets represent 43.3% of total assets in 2021, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 7.6% of total assets in 2021, up from 4.6% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 18.4% of total assets.
Acura Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Acura Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Acura Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Acura Pharmaceuticals Inc generates 1.82x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Acura Pharmaceuticals Inc is currently not profitable relative to its asset base.
Acura Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.86 | 1.37 | 1.69 |
| Quick Ratio | 0.86 | 1.37 | 1.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-135.00K | $ 438.00K | $ 2.42 Million |
Acura Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Acura Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 24.11 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -50.5% |
| Total Assets | $860.00K |
| Market Capitalization | $13.20K USD |
Valuation Analysis
Below Book Valuation: The market values Acura Pharmaceuticals Inc's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Acura Pharmaceuticals Inc's assets decreased by 50.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Acura Pharmaceuticals Inc (2000–2021)
The table below shows the annual total assets of Acura Pharmaceuticals Inc from 2000 to 2021.
| Year | Total Assets | Change |
|---|---|---|
| 2021-12-31 | $860.00K | -50.46% |
| 2020-12-31 | $1.74 Million | -32.24% |
| 2019-12-31 | $2.56 Million | +19.05% |
| 2018-12-31 | $2.15 Million | -53.26% |
| 2017-12-31 | $4.60 Million | -43.91% |
| 2016-12-31 | $8.21 Million | -51.61% |
| 2015-12-31 | $16.96 Million | +5.79% |
| 2014-12-31 | $16.03 Million | -44.00% |
| 2013-12-31 | $28.63 Million | -1.46% |
| 2012-12-31 | $29.05 Million | -21.84% |
| 2011-12-31 | $37.17 Million | +45.82% |
| 2010-12-31 | $25.49 Million | -20.13% |
| 2009-12-31 | $31.92 Million | -25.71% |
| 2008-12-31 | $42.96 Million | -5.85% |
| 2007-12-31 | $45.63 Million | +2718.28% |
| 2006-12-31 | $1.62 Million | -9.65% |
| 2005-12-31 | $1.79 Million | -63.92% |
| 2004-12-31 | $4.97 Million | -24.99% |
| 2003-12-31 | $6.62 Million | -65.80% |
| 2002-12-31 | $19.36 Million | +74.94% |
| 2001-12-31 | $11.07 Million | -27.22% |
| 2000-12-31 | $15.21 Million | -- |